SLC19A1/RFC1 (extracellular) Blocking Peptide (#BLP-FT001) is the original antigen used for immunization during Anti-SLC19A1/RFC1 (extracellular) Antibody (#AFT-001) generation. The blocking peptide binds and ‘blocks’ Anti-SLC19A1/RFC1 (extracellular) primary antibody, this makes it a good negative reagent control to help confirm antibody specificity in western blot and immunohistochemistry applications. This control is also often called a pre-adsorption control.
- Western blot analysis of rat brain membranes (lanes 1 and 5), mouse brain membranes (lanes 2 and 6), rat small intestine lysate (lanes 3 and 7) and rat liver membranes (lanes 4 and 8):
- Western blot analysis of human MCF-7 breast adenocarcinoma cell line lysate (lanes 1 and 3) and human K562 myelogenous leukemia cell line lysate (lanes 2 and 4):
- Expression of SLC19A1 in rat hippocampus.Immunohistochemical staining of perfusion-fixed frozen rat brain sections with Anti-SLC19A1/RFC1 (extracellular) Antibody (#AFT-001), (1:1200), followed by goat anti-rabbit-AlexaFluor-488. A. Staining in the rat hippocampal CA3 region, showed immunoreactivity (green) in neuronal profiles in the pyramidal layer (arrows). B. Pre-incubation of the antibody with SLC19A1/RFC1 (extracellular) Blocking Peptide (BLP-FT001), suppressed staining. Cell nuclei are stained with DAPI (blue). P = pyramidal layer.
- Peptide (C)SDKRGLGLQVRDQFR, corresponding to amino acid residues 412 - 426 of mouse SLC19A1 (Accession P41438).